HC Wainwright & Co. Reiterates Neutral on IGM Biosciences, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Neutral rating for IGM Biosciences (NASDAQ:IGMS) and maintained a $12 price target.
May 24, 2024 | 10:22 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Robert Burns has reiterated a Neutral rating for IGM Biosciences and maintained a $12 price target.
The reiteration of a Neutral rating and maintenance of the $12 price target suggests that the analyst does not foresee significant short-term changes in the stock's performance. This is likely to result in a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100